

CITATION REPORT

List of articles citing

A listing of human tumor antigens recognized by T cells: March 2004 update

DOI: 10.1007/s00262-004-0560-6

Cancer Immunology, Immunotherapy, 2005, 54, 187-207.

Source: <https://exaly.com/paper-pdf/38410980/citation-report.pdf>

Version: 2024-04-28

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
396	Adaptive immunity in cancer immunology and therapeutics. 2014 , 8, 441		26
395	Immune mechanisms in neoplasia. 2004 , 1, 375-381		
394	Vaccine strategies to treat lymphoproliferative disorders. 2005 , 37, 534-50		10
393	Combining radiotherapy and immunotherapy: a revived partnership. 2005 , 63, 655-66		265
392	Human leukocyte antigen (HLA) class I defects in head and neck cancer: molecular mechanisms and clinical significance. 2005 , 33, 113-33		84
391	The immunotherapy of prostate and bladder cancer. 2005 , 96, 728-35		12
390	Immunotherapy and chemotherapy—a practical partnership. 2005 , 5, 397-405		539
389	Regulators of apoptosis: suitable targets for immune therapy of cancer. 2005 , 4, 399-409		86
388	Anti-tumor antibodies in ovarian cancer. 2005 , 54, 55-62		30
387	Liposome-polycation-DNA (LPD) particle as a carrier and adjuvant for protein-based vaccines: therapeutic effect against cervical cancer. <i>Cancer Immunology, Immunotherapy</i> , 2005 , 54, 1180-90	7.4	72
386	Regulatory T cells and tumor immunity. <i>Cancer Immunology, Immunotherapy</i> , 2005 , 54, 1153-61	7.4	75
385	New target antigens for cancer immunoprevention. 2005 , 5, 221-8		12
384	Identification of noncanonical melanoma-associated T cell epitopes for cancer immunotherapy. 2005 , 174, 6716-24		28
383	Getting to the surface: a link between tumor antigen discovery and natural presentation of peptide-MHC complexes. 2005 , 11, 5333-6		5
382	Immunoinformatics and its relevance to understanding human immune disease. 2005 , 1, 145-57		42
381	Therapeutic vaccination in patients with gastrointestinal malignancies. A review of immunological and clinical results. 2005 , 16, 847-62		54
380	Anaplastic lymphoma kinase and its signalling molecules as novel targets in lymphoma therapy. <i>Expert Opinion on Therapeutic Targets</i> , 2005 , 9, 515-32	6.4	16

379	Increased immunogenicity of an anchor-modified tumor-associated antigen is due to the enhanced stability of the peptide/MHC complex: implications for vaccine design. 2005 , 174, 4812-20	89
378	Tumor-associated antigen preferentially expressed antigen of melanoma (PRAME) induces caspase-independent cell death in vitro and reduces tumorigenicity in vivo. 2005 , 65, 7348-55	46
377	Recruitment of latent pools of high-avidity CD8(+) T cells to the antitumor immune response. 2005 , 201, 1591-602	369
376	Lessons from reproductive immunology for other fields of immunology and clinical approaches. 2005 , 89, 169-179	7
375	Recent developments in therapeutic cancer vaccines. 2005 , 2, 108-13	41
374	Immunotherapy for gynaecological malignancies. 2005 , 5, 1193-210	30
373	Escape strategies and reasons for failure in the interaction between tumour cells and the immune system: how can we tilt the balance towards immune-mediated cancer control?. 2005 , 5, 463-76	54
372	Soluble T cell receptors: novel immunotherapies. 2005 , 5, 438-43	30
371	Progress and controversies in developing cancer vaccines. 2005 , 3, 18	42
370	A generic RNA-pulsed dendritic cell vaccine strategy for renal cell carcinoma. 2005 , 3, 29	18
369	A quest for therapeutic antigens in bone and soft tissue sarcoma. 2005 , 3, 31	14
368	Towards therapeutic vaccines for colorectal carcinoma: a review of clinical trials. 2005 , 4, 329-50	48
367	MODELING TUMOR IMMUNOLOGY. 2006 , 16, 1091-1124	28
366	Microarray evidence of glutaminyl cyclase gene expression in melanoma: implications for tumor antigen specific immunotherapy. 2006 , 4, 27	11
365	Improved overall survival in dendritic cell vaccination-induced immunoreactive subgroup of advanced melanoma patients. 2006 , 4, 36	35
364	Is there a role for immunotherapy in hepatocellular carcinoma?. 2006 , 38, 221-5	14
363	Processing sites are different in the generation of HLA-A2.1-restricted, T cell reactive tumor antigen epitopes and viral epitopes. 2006 , 19, 853-70	21
362	Expression of tumor-associated antigens in acute myeloid leukemia: Implications for specific immunotherapeutic approaches. 2006 , 108, 4109-17	156

361	Targeting self-antigens through allogeneic TCR gene transfer. 2006 , 108, 870-7		51
360	Bibliography. Current world literature. Myeloid disease. 2006 , 13, 99-117		
359	A Strategy for the Identification of Canonical and Non-canonical MHC I-binding Epitopes Using an ANN-based Epitope Prediction Algorithm. 2006 , 25, 350-358		5
358	Detection of autoantibodies to the BTB-kelch protein KLHL7 in cancer sera. 2006 , 64, 325-35		15
357	Cytotoxic T cells. 2006 , 126, 32-41		235
356	Codon optimized expression of HPV 16 E6 renders target cells susceptible to E6-specific CTL recognition. 2006 , 107, 41-9		20
355	DNA vaccines for cancer too. <i>Cancer Immunology, Immunotherapy</i> , 2006 , 55, 119-30	7.4	24
354	Identification of identical TCRs in primary melanoma lesions and tumor free corresponding sentinel lymph nodes. <i>Cancer Immunology, Immunotherapy</i> , 2006 , 55, 495-502	7.4	15
353	Defining MHC class II T helper epitopes for WT1 tumor antigen. <i>Cancer Immunology, Immunotherapy</i> , 2006 , 55, 850-60	7.4	35
352	Circulating IL-8 and anti-IL-8 autoantibody in patients with ovarian cancer. 2006 , 102, 244-51		111
351	Vaccine therapy of malignant melanoma. 2006 , 6, 217-230		2
350	Proteasome-inhibited dendritic cells demonstrate improved presentation of exogenous synthetic and natural HLA-class I peptide epitopes. 2006 , 308, 77-89		10
349	CD8 T-cell recognition of human 5T4 oncofetal antigen. 2006 , 119, 1638-47		24
348	Vaccines for Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2006 , 1, 93-104	8.9	6
347	Cancer-testis antigens in tumor biology and immunotherapy. 2006 , 5, 1226-7		6
346	DNA damage and tumor surveillance: one trigger for two pathways. 2006 , 2006, pe2		15
345	HPtaa database-potential target genes for clinical diagnosis and immunotherapy of human carcinoma. 2006 , 34, D607-12		19
344	Immunity to melanoma antigens: from self-tolerance to immunotherapy. 2006 , 90, 243-95		53

343	Immune escape associated with functional defects in antigen-processing machinery in head and neck cancer. 2006 , 12, 3890-5	174
342	The wild-type sequence (wt) p53(25-35) peptide induces HLA-DR7 and HLA-DR11-restricted CD4+ Th cells capable of enhancing the ex vivo expansion and function of anti-wt p53(264-272) peptide CD8+ T cells. 2006 , 177, 6795-803	18
341	Peptide and dendritic cell vaccines. 2006 , 12, 2342s-2345s	27
340	Unique tumor antigens: evidence for immune control of genome integrity and immunogenic targets for T cell-mediated patient-specific immunotherapy. 2006 , 12, 5023-32	55
339	Tumor antigens as surrogate markers and targets for therapy and vaccines. 2007 , 96, 175-90	16
338	Clinical and immunologic responses to active specific cancer vaccines in human colorectal cancer. 2006 , 12, 3064-9	90
337	Association of antigen-processing machinery and HLA antigen phenotype of melanoma cells with survival in American Joint Committee on Cancer stage III and IV melanoma patients. 2006 , 66, 6405-11	54
336	Alterations in the T-cell receptor variable beta gene-restricted profile of CD8+ T lymphocytes in the peripheral circulation of patients with squamous cell carcinoma of the head and neck. 2006 , 12, 2394-403	21
335	Advanced liposomal vectors as cancer vaccines in melanoma immunotherapy. 2006 , 16, 195-204	10
334	Clinical applications of virosomes in cancer immunotherapy. 2006 , 6, 1113-21	10
333	Generation of T cell help through a MHC class I-restricted TCR. 2006 , 177, 976-82	37
332	Homeostatic proliferation as an isolated variable reverses CD8+ T cell anergy and promotes tumor rejection. 2006 , 177, 4521-9	73
331	Overcoming original antigenic sin to generate new CD8 T cell IFN-gamma responses in an antigen-experienced host. 2006 , 177, 2873-9	27
330	Antibody targeting to a class I MHC-peptide epitope promotes tumor cell death. 2006 , 177, 4187-95	43
329	Vaccination: role in metastatic melanoma. 2006 , 6, 1305-18	21
328	Identification of HLA-CW3, GNAS and IMPA as cytotoxic T-lymphocyte (CTL) target antigens using an allogeneic mixed lymphocyte tumor cell culture (MLTC) system and subsequent cDNA library screening. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2007 , 22, 206-22	3,9 1
327	Unique human tumor antigens: immunobiology and use in clinical trials. 2007 , 178, 1975-9	132
326	Decreased tumor surveillance after adoptive T-cell therapy. 2007 , 67, 7467-76	16

325	Tumors hamper the immunogenic competence of CD4+ T cell-directed dendritic cell vaccination. 2007 , 179, 2899-909		11
324	Identification of human aldehyde dehydrogenase 1 family member A1 as a novel CD8+ T-cell-defined tumor antigen in squamous cell carcinoma of the head and neck. 2007 , 67, 10538-45		119
323	HLA-G as a target molecule in specific immunotherapy against renal cell carcinoma. <i>Oncology Reports</i> , 2007 , 18, 1463	3-5	5
322	Anti-tumor vaccines in head and neck cancer: targeting immune responses to the tumor. 2007 , 7, 633-42		23
321	Universal and stemness-related tumor antigens: potential use in cancer immunotherapy. 2007 , 13, 5675-9		30
320	Altered immune function during long-term host-tumor interactions can be modulated to retard autochthonous neoplastic growth. 2007 , 179, 2851-9		58
319	Identification and characterization of T-cell epitopes deduced from RGS5, a novel broadly expressed tumor antigen. 2007 , 13, 3347-55		39
318	Shared MHC class II-dependent melanoma ribosomal protein L8 identified by phage display. 2007 , 67, 3555-9		9
317	The HLA A*0201-restricted hTERT(540-548) peptide is not detected on tumor cells by a CTL clone or a high-affinity T-cell receptor. 2007 , 6, 2081-91		39
316	Allorestricted T cells with specificity for the FMNL1-derived peptide PP2 have potent antitumor activity against hematologic and other malignancies. 2007 , 110, 2931-9		39
315	Cytokines as Vaccine Adjuvants. 327-354		4
314	Melanoma immunology: past, present and future. 2007 , 19, 121-7		47
313	Mimotope vaccines for cancer immunotherapy. 2007 , 25, 3032-7		23
312	Potential target antigens for immunotherapy in human pancreatic cancer. <i>Cancer Letters</i> , 2007 , 252, 290-8	9-9	24
311	Use of multicellular tumor spheroids to dissect endothelial cell-tumor cell interactions: a role for T-cadherin in tumor angiogenesis. 2007 , 581, 4523-8		57
310	General Principles of Tumor Immunotherapy. 2007 ,		2
309	Tumor Antigens. 2007 , 17-31		
308	Current immunotherapeutic strategies in colon cancer. 2007 , 16, 873-900, x		10

307	Immunogenicity of dendritic-tumor fusion hybrids and their utility in cancer immunotherapy. 2007 , 27, 463-83		21
306	. 2007 ,		13
305	Cancer/testis antigen expression and specific cytotoxic T lymphocyte responses in non small cell lung cancer. 2007 , 120, 337-43		47
304	Immunological characterization of missense mutations occurring within cytotoxic T cell-defined p53 epitopes in HLA-A*0201+ squamous cell carcinomas of the head and neck. 2007 , 120, 2618-24		28
303	Peptide binding specificity of the chaperone calreticulin. 2007 , 1774, 701-13		24
302	Cancer testis/germline antigens (CT/CG-antigens) in leukemias. 2007 , 31, 1-3		9
301	Epigenetic regulation of PRAME gene in chronic myeloid leukemia. 2007 , 31, 1521-8		51
300	Anti-tumor and anti-ovarian autoantibodies in women with ovarian cancer. 2007 , 57, 243-9		25
299	Identification of T-cell epitopes for cancer immunotherapy. 2007 , 21, 1859-74		102
298	Immunological evaluation of personalized peptide vaccination in combination with a 5-fluorouracil derivative (TS-1) for advanced gastric or colorectal carcinoma patients. <i>Cancer Science</i> , 2007 , 98, 1113-9 ^{6.9}		47
297	The role of regulatory T cells in ovarian cancer. 2007 , 17, 764-70		13
296	Phase I trial of an enhanced prostate-specific antigen-based vaccine and anti-CTLA-4 antibody in patients with metastatic androgen-independent prostate cancer. 2007 , 5, 347-50		10
295	Novel tumor antigens elicit anti-tumor humoral immune reactions in a subset of patients with polycythemia vera. 2007 , 122, 279-87		24
294	Mobilizing the low-avidity T cell repertoire to kill tumors. <i>Seminars in Cancer Biology</i> , 2007 , 17, 317-29	12.7	41
293	Adoptive cell transfer therapy. 2007 , 34, 524-31		90
292	Infusion of Melan-A/Mart-1 specific tumor-infiltrating lymphocytes enhanced relapse-free survival of melanoma patients. <i>Cancer Immunology, Immunotherapy</i> , 2007 , 56, 515-26	7.4	36
291	Vaccination therapy in prostate cancer. <i>Cancer Immunology, Immunotherapy</i> , 2007 , 56, 429-45	7.4	18
290	HAGE, a cancer/testis antigen with potential for melanoma immunotherapy: identification of several MHC class I/II HAGE-derived immunogenic peptides. <i>Cancer Immunology, Immunotherapy</i> , 2007 , 56, 1885-95	7.4	22

289	Current approaches in dendritic cell generation and future implications for cancer immunotherapy. <i>Cancer Immunology, Immunotherapy</i> , 2007 , 56, 1513-37	7.4	130
288	Low TCR avidity and lack of tumor cell recognition in CD8(+) T cells primed with the CEA-analogue CAP1-6D peptide. <i>Cancer Immunology, Immunotherapy</i> , 2007 , 56, 1979-91	7.4	18
287	Dynamic cross-talk between tumor and immune cells in orchestrating the immunosuppressive network at the tumor microenvironment. <i>Cancer Immunology, Immunotherapy</i> , 2007 , 56, 1687-700	7.4	155
286	Towards progress on DNA vaccines for cancer. 2007 , 64, 2391-403		31
285	Immunological profiling of a panel of human ovarian cancer cell lines. <i>Cancer Immunology, Immunotherapy</i> , 2008 , 57, 31-42	7.4	12
284	A HLA-Cw*0701 restricted Melan-A/MART1 epitope presented by melanoma tumor cells to CD8+ tumor infiltrating lymphocytes. <i>Cancer Immunology, Immunotherapy</i> , 2008 , 57, 745-52	7.4	5
283	Dendritic cell-based vaccines suppress metastatic liver tumor via activation of local innate and acquired immunity. <i>Cancer Immunology, Immunotherapy</i> , 2008 , 57, 1861-9	7.4	19
282	RhoC a new target for therapeutic vaccination against metastatic cancer. <i>Cancer Immunology, Immunotherapy</i> , 2008 , 57, 1871-8	7.4	18
281	Current status of peptide vaccines for cancer immunotherapy in malignant myeloid diseases. 2008 , 1, 223-226		0
280	Peptide epitope identification for tumor-reactive CD4 T cells. 2008 , 20, 221-7		41
279	The immune system--is it relevant to cancer development, progression and treatment?. 2008 , 20, 101-12		74
278	Antigens for cancer immunotherapy. 2008 , 20, 286-95		131
277	Humoral immune responses against tumor-associated antigen OVA66 originally defined by serological analysis of recombinant cDNA expression libraries and its potentiality in cellular immunity. <i>Cancer Science</i> , 2008 , 99, 1670-8	6.9	17
276	Leukemia-associated antigens as target structures for a specific immunotherapy in chronic myeloid leukemia. 2008 , 80, 461-8		18
275	Cell surface molecular changes associated with apoptosis. 2008 , 57-73		
274	Unmet need in lung cancer: can vaccines bridge the gap?. 2008 , 9 Suppl 1, S6-12		6
273	Dendritic cells in cancer immunotherapy. 2008 , 99, 363-407		55
272	HLA-A2-restricted cytotoxic T lymphocyte epitopes from human heparanase as novel targets for broad-spectrum tumor immunotherapy. 2008 , 10, 977-86		33

271	Variation in cytotoxic T-lymphocyte responses to peptides derived from tyrosinase-related protein-2. 2008 , 69, 24-31	2
270	New dimensions in tumor immunology: what does 3D culture reveal?. 2008 , 14, 333-40	104
269	Assessing vaccine potency using TCRmimic antibodies. 2008 , 26, 3092-102	15
268	Prospects and challenges of building a cancer vaccine targeting telomerase. 2008 , 90, 173-80	40
267	Dendritic cells and cytokines in immune rejection of cancer. 2008 , 19, 93-107	52
266	Telomerase as a universal tumor antigen for cancer vaccines. 2008 , 7, 881-7	48
265	Treatment options for paracoccidioidomycosis and new strategies investigated. 2008 , 6, 251-62	58
264	Porphyrin-bile acid conjugates: from saccharide recognition in the solution to the selective cancer cell fluorescence detection. 2008 , 6, 1548-52	42
263	Tumor associated antigen PRAME is a marker of favorable prognosis in childhood acute myeloid leukemia patients and modifies the expression of S100A4, Hsp 27, p21, IL-8 and IGFBP-2 in vitro and in vivo. 2008 , 49, 1123-31	16
262	Bioactive Natural Peptides. 2008 , 35, 597-691	14
261	Distinct CD8+ T cell repertoires primed with agonist and native peptides derived from a tumor-associated antigen. 2008 , 180, 1526-34	37
260	Phase I study and preliminary pharmacology of the novel innate immune modulator rBBX-01 in gynecologic cancers. 2008 , 14, 3089-97	9
259	Oncolytic viruses: a novel form of immunotherapy. 2008 , 8, 1581-8	129
258	Identification of human T cell receptor gammadelta-recognized epitopes/proteins via CDR3delta peptide-based immunobiochemical strategy. <i>Journal of Biological Chemistry</i> , 2008 , 283, 12528-37	5-4 54
257	Matrilysin (MMP-7) is a novel broadly expressed tumor antigen recognized by antigen-specific T cells. 2008 , 14, 5503-11	55
256	A safeguard eliminates T cell receptor gene-modified autoreactive T cells after adoptive transfer. 2008 , 105, 623-8	75
255	Regulated expression of a tumor-associated antigen reveals multiple levels of T-cell tolerance in a mouse model of lung cancer. 2008 , 68, 9459-68	38
254	Induction of both CD8+ and CD4+ T-cell-mediated responses in colorectal cancer patients by colon antigen-1. 2008 , 14, 7292-303	9

253	Anticancer immunotherapy in combination with proapoptotic therapy. 2008 , 8, 666-75	15
252	Dendritic cell based immunotherapy--a promising therapeutic approach for endocrine malignancies. 2008 , 40, 89-98	11
251	Tumor infection by oncolytic reovirus primes adaptive antitumor immunity. 2008 , 14, 7358-66	136
250	Immunotherapy for gastrointestinal cancer: current status and strategies for improving efficacy. 2008 , 8, 385-95	17
249	Immunotherapy opportunities in ovarian cancer. 2008 , 8, 243-57	52
248	MAGE-B2 autoantibody: a new biomarker for pediatric systemic lupus erythematosus. 2008 , 35, 2430-8	8
247	Lymphocyte Biomarkers of Clinical Responses to Adoptive Immunotherapy of Malignant Melanoma. 2008 , 4, 125-129	2
246	The TAG family of cancer/testis antigens is widely expressed in a variety of malignancies and gives rise to HLA-A2-restricted epitopes. 2008 , 31, 7-17	8
245	MHC class I TCR engineered anti-tumor CD4 T cells: implications for cancer immunotherapy. 2009 , 9, 344-52	7
244	CD8 T-cell responses against cyclin B1 in breast cancer patients with tumors overexpressing p53. 2009 , 15, 1543-9	12
243	Multipeptide vaccination in cancer patients. 2009 , 9, 1043-55	48
242	Differential baseline and response profile to IFN-gamma gene transduction of IL-6/IL-6 receptor-alpha secretion discriminate primary tumors versus bone marrow metastases of nasopharyngeal carcinomas in culture. 2009 , 9, 169	3
241	MAGRIT: the largest-ever phase III lung cancer trial aims to establish a novel tumor-specific approach to therapy. 2009 , 10, 371-4	145
240	CTL induction by cross-priming is restricted to immunodominant epitopes. 2009 , 39, 704-16	16
239	DNA vaccination with a mutated p53 allele induces specific cytolytic T cells and protects against tumor cell growth and the formation of metastasis. 2009 , 135, 567-80	2
238	Standards und Trends bei der Behandlung des malignen Melanoms. 2009 , 2, 101-113	
237	A phase II study of fotemustine plus dacarbazine with dendritic cell vaccines as first-line therapy for Chinese patients with advanced acral lentiginous melanoma. 2009 , 21, 13-19	
236	Antitumor activity of a self-adjuvanting glyco-lipopeptide vaccine bearing B cell, CD4+ and CD8+ T cell epitopes. <i>Cancer Immunology, Immunotherapy</i> , 2009 , 58, 187-200	7.4 65

235	Focal adhesion kinase as an immunotherapeutic target. <i>Cancer Immunology, Immunotherapy</i> , 2009 , 58, 931-40	7.4	4
234	Modified peptides in anti-cancer vaccines: are we eventually improving anti-tumour immunity?. <i>Cancer Immunology, Immunotherapy</i> , 2009 , 58, 1159-67	7.4	19
233	Targets for active immunotherapy against pediatric solid tumors. <i>Cancer Immunology, Immunotherapy</i> , 2009 , 58, 831-41	7.4	9
232	HLA and melanoma: multiple alterations in HLA class I and II expression in human melanoma cell lines from ESTDAB cell bank. <i>Cancer Immunology, Immunotherapy</i> , 2009 , 58, 1507-15	7.4	42
231	Identification and modification of an HLA-A*0201-restricted cytotoxic T lymphocyte epitope from Ran antigen. <i>Cancer Immunology, Immunotherapy</i> , 2009 , 58, 2039-49	7.4	8
230	Induction of anti-tumour immunity by dendritic cells transduced with hTERT recombinant adenovirus in mice. 2009 , 217, 685-92		16
229	Allogeneic cell therapy from immunized donors with tumor antigen peptide enhances the antitumor effect after cyclophosphamide-using non-myeloablative allogeneic hematopoietic cell transplantation. <i>Cancer Science</i> , 2009 , 100, 138-43	6.9	1
228	Dendritic cell-based human immunodeficiency virus vaccine. 2009 , 265, 138-58		72
227	A phase I trial of intratumoral administration of recombinant oncolytic adenovirus overexpressing HSP70 in advanced solid tumor patients. 2009 , 16, 376-82		91
226	Characterization of BAX inhibitor-1 as a novel leukemia-associated antigen. 2009 , 23, 1818-24		10
225	Adoptive immunotherapy using human peripheral blood lymphocytes transferred with RNA encoding Her-2/neu-specific chimeric immune receptor in ovarian cancer xenograft model. 2009 , 16, 489-97		78
224	The feasibility of establishing a programme of adjuvant autologous vaccination for renal cell carcinoma. 2009 , 103, 740-6		3
223	Multi-peptide vaccines viald as peptide mixtures can be stable reagents for use in peptide-based immune therapies. 2009 , 27, 1764-70		15
222	Immunosuppressive mechanisms in cancer: consequences for the development of therapeutic vaccines. 2009 , 27, 3398-400		8
221	Immunotherapy in colorectal cancer. 2009 , 44, 261-8		2
220	Recent advances in multivalent self adjuvanting glycolipopeptide vaccine strategies against breast cancer. 2009 , 57, 409-23		13
219	Clinical grade OK432-activated dendritic cells: in vitro characterization and tracking during intralymphatic delivery. 2009 , 32, 66-78		13
218	CD4+ T-cell clones recognizing human lymphoma-associated antigens: generation by in vitro stimulation with autologous Epstein-Barr virus-transformed B cells. 2009 , 114, 807-15		15

217	Immunotherapy of childhood cancer: from biologic understanding to clinical application. 2010 , 22, 2-11		15
216	Therapeutic Cancer Vaccines. 2010 , 6, 163-174		1
215	Alterations of HLA class I expression in human melanoma xenografts in immunodeficient mice occur frequently and are associated with higher tumorigenicity. <i>Cancer Immunology, Immunotherapy</i> , 2010 , 59, 13-26	7.4	23
214	Identification of a 17beta-hydroxysteroid dehydrogenase type 12 pseudogene as the source of a highly restricted BALB/c Meth A tumor rejection peptide. <i>Cancer Immunology, Immunotherapy</i> , 2010 , 59, 113-24	7.4	8
213	Direct discovery and validation of a peptide/MHC epitope expressed in primary human breast cancer cells using a TCRm monoclonal antibody with profound antitumor properties. <i>Cancer Immunology, Immunotherapy</i> , 2010 , 59, 563-73	7.4	20
212	Immunogenic chemotherapy with cyclophosphamide and doxorubicin against established murine carcinoma. <i>Cancer Immunology, Immunotherapy</i> , 2010 , 59, 769-77	7.4	46
211	Immunotherapy using allogeneic squamous cell tumor-dendritic cell fusion hybrids. 2010 , 32, 1209-16		5
210	Induction of tumour immunity by targeted inhibition of nonsense-mediated mRNA decay. 2010 , 465, 227-30		192
209	Ex vivo- and in vivo-induced dead tumor cells as modulators of antitumor responses. 2010 , 1209, 109-17		19
208	Soluble plasma HLA peptidome as a potential source for cancer biomarkers. 2010 , 107, 18769-76		93
207	Vaccines and immunotherapeutics for the treatment of malignant disease. 2010 , 2010, 697158		25
206	In vivo imaging of an inducible oncogenic tumor antigen visualizes tumor progression and predicts CTL tolerance. 2010 , 184, 2930-8		10
205	The angiogenic growth factor and biomarker midkine is a tumor-shared antigen. 2010 , 185, 418-23		21
204	Current vaccine updates for lung cancer. 2010 , 9, 323-35		4
203	Peptide vaccines prevent tumor growth by activating T cells that respond to native tumor antigens. 2010 , 107, 4652-7		37
202	When gene therapy meets adoptive cell therapy: better days ahead for cancer immunotherapy?. 2010 , 9, 359-63		3
201	Intranodal immunization with a vaccinia virus encoding multiple antigenic epitopes and costimulatory molecules in metastatic melanoma. 2010 , 18, 651-9		43
200	T cell-tumor interaction directs the development of immunotherapies in head and neck cancer. 2010 , 2010, 236378		29

199	Enhanced T cell receptor gene therapy for cancer. 2010 , 10, 749-62		11
198	Antigen-experienced CD4(+) T cells limit naïve T-cell priming in response to therapeutic vaccination in vivo. 2010 , 70, 6161-70		5
197	Macrophages as mediators of tumor immunosurveillance. 2010 , 31, 212-9		168
196	Whole tumor antigen vaccines. 2010 , 22, 132-43		147
195	The evolving role of dendritic cells in cancer therapy. 2010 , 10, 369-79		32
194	Immunotherapy for metastatic solid cancers. 2011 , 45, 341-60		63
193	Cancer immunotherapy comes of age. 2011 , 480, 480-9		2374
192	Protein Microarray for Disease Analysis. <i>Methods in Molecular Biology</i> , 2011 ,	1.4	2
191	Colorectal cancer vaccines in clinical trials. 2011 , 10, 899-921		23
190	Development of novel targeted agents in the treatment of metastatic colorectal cancer. 2011 , 10, 266-78		5
189	Proteomics for development of vaccine. <i>Journal of Proteomics</i> , 2011 , 74, 2596-616	3.9	31
188	Database resources for proteomics-based analysis of cancer. <i>Methods in Molecular Biology</i> , 2011 , 723, 349-64	1.4	6
187	Pattern and clinical significance of cancer-testis gene expression in head and neck squamous cell carcinoma. 2011 , 128, 2625-34		57
186	Personalized therapy for non-small cell lung cancer: which drug for which patient?. 2011 , 23, 281-90		9
185	Heparanase: a universal immunotherapeutic target in human cancers. 2011 , 16, 412-7		20
184	Immunotherapy. 587-599		
183	The present and future of peptide vaccines for cancer: single or multiple, long or short, alone or in combination?. 2011 , 17, 343-50		198
182	Vaccines and other immunological approaches for cancer immunoprevention. 2011 , 12, 1957-73		28

181	A phase I study of personalized peptide vaccination for advanced urothelial carcinoma patients who failed treatment with methotrexate, vinblastine, adriamycin and cisplatin. 2011 , 108, 831-8		16
180	Immunological perspective of self versus tumor antigens: insights from the RIP-gp model. 2011 , 241, 164-79		16
179	Endogenous T cell responses to antigens expressed in lung adenocarcinomas delay malignant tumor progression. 2011 , 19, 72-85		159
178	On the use of donor-derived iNKT cells for adoptive immunotherapy to prevent leukemia recurrence in pediatric recipients of HLA haploidentical HSCT for hematological malignancies. 2011 , 140, 152-9		23
177	Translating tumor antigens into cancer vaccines. 2011 , 18, 23-34		148
176	Identification of a cyclin B1-derived CTL epitope eliciting spontaneous responses in both cancer patients and healthy donors. <i>Cancer Immunology, Immunotherapy</i> , 2011 , 60, 227-34	7.4	8
175	CTL recognition of a novel HLA-A*0201-binding peptide derived from glioblastoma multiforme tumor cells. <i>Cancer Immunology, Immunotherapy</i> , 2011 , 60, 1319-32	7.4	4
174	Immuno-cell therapy with antecedent surgery has superior actuarial survival to immuno-cell therapy without antecedent surgery for advanced cancers. <i>Cancer Immunology, Immunotherapy</i> , 2011 , 60, 1397-403	7.4	2
173	Cancer vaccines. Any future?. 2011 , 59, 249-59		12
172	Tumour-associated antigens: considerations for their use in tumour immunotherapy. 2011 , 93, 263-273		8
171	Resection of non-small cell lung cancers reverses tumor-induced gene expression changes in the peripheral immune system. 2011 , 17, 5867-77		40
170	Randomized multicenter trial of the effects of melanoma-associated helper peptides and cyclophosphamide on the immunogenicity of a multi-peptide melanoma vaccine. 2011 , 29, 2924-32		88
169	Dendritic cells in the pathogenesis and treatment of human diseases: a Janus Bifrons?. <i>Immunotherapy</i> , 2011 , 3, 1203-22	3.8	30
168	Vaccination therapy for non-small-cell lung cancer: review of agents in phase III development. 2012 , 23, 1387-93		45
167	Selected anti-tumor vaccines merit a place in multimodal tumor therapies. 2012 , 2, 132		20
166	T-Cell Mediated Immune Responses Induced in ret Transgenic Mouse Model of Malignant Melanoma. <i>Cancers</i> , 2012 , 4, 490-503	6.6	14
165	T-cell-receptor-like antibodies - generation, function and applications. 2012 , 14, e6		51
164	Dissection of T-cell antigen specificity in human melanoma. 2012 , 72, 1642-50		117

163	How (specific) would like your T-cells today? Generating T-cell therapeutic function through TCR-gene transfer. <i>Frontiers in Immunology</i> , 2012 , 3, 186	8.4	13
162	New Challenges for Cancer Systems Biomedicine. <i>SIMAI Springer Series</i> , 2012 ,		6
161	Mathematical and Computational Models in Tumor Immunology. 2012 , 7, 186-203		28
160	Incorporation of transmembrane hydrophobic mutations in the TCR enhance its surface expression and T cell functional avidity. 2012 , 188, 5538-46		46
159	Cancer immunoediting in malignant glioma. 2012 , 71, 201-22; discussion 222-3		62
158	MHC class I molecules act as tumor suppressor genes regulating the cell cycle gene expression, invasion and intrinsic tumorigenicity of melanoma cells. 2012 , 33, 687-93		63
157	A novel cytotoxic T lymphocyte epitope analogue with enhanced activity derived from cyclooxygenase-2. 2012 , 76, 278-85		6
156	Oncolytic immunotherapy of advanced solid tumors with a CD40L-expressing replicating adenovirus: assessment of safety and immunologic responses in patients. 2012 , 72, 1621-31		100
155	Ex vivo enrichment of circulating anti-tumor T cells from both cutaneous and ocular melanoma patients: clinical implications for adoptive cell transfer therapy. <i>Cancer Immunology, Immunotherapy</i> , 2012 , 61, 1169-82	7.4	2
154	Detection of orphan receptor tyrosine kinase (ROR-1) expression in Egyptian pediatric acute lymphoblastic leukemia. 2012 , 31, 113-9		3
153	Efficient induction of specific cytotoxic T lymphocytes against gastric adenocarcinoma by a survivin peptide. 2012 , 90, 701-8		8
152	Antitumor effect of new multiple antigen peptide based on HLA-A0201-restricted CTL epitopes of human telomerase reverse transcriptase (hTERT). <i>Cancer Science</i> , 2012 , 103, 1920-8	6.9	13
151	Identification of prostate-specific G-protein coupled receptor as a tumor antigen recognized by CD8(+) T cells for cancer immunotherapy. <i>PLoS ONE</i> , 2012 , 7, e45756	3.7	11
150	Re-directed T cells for the treatment of fibroblast activation protein (FAP)-positive malignant pleural mesothelioma (FAPME-1). 2012 , 12, 615		47
149	Optimal vaccination schedule search using genetic algorithm over MPI technology. 2012 , 12, 129		4
148	The tumour suppressor Fhit positively regulates MHC class I expression on cancer cells. 2012 , 227, 367-79		33
147	Active-specific immunotherapy of human cancers with the heat shock protein Gp96-revisited. 2012 , 130, 2219-31		40
146	Muscle CARs and TcRs: turbo-charged technologies for the (T cell) masses. <i>Cancer Immunology, Immunotherapy</i> , 2012 , 61, 127-35	7.4	18

145	Nanoengineering approaches to the design of artificial antigen-presenting cells. 2013 , 8, 1173-89		55
144	Synergistical toll-like receptors activated dendritic cells induce antitumor effects against carcinoembryonic antigen-expressing colon cancer. 2013 , 28, 25-33		12
143	Increasing immunogenicity of cancer vaccines to improve their clinical outcome. 2013 , 12, 1111-3		4
142	Literature classification for semi-automated updating of biological knowledgebases. 2013 , 14 Suppl 5, S14		8
141	Dendritic cell-based immunotherapy for colon cancer using an HLA-A*0201-restricted cytotoxic T-lymphocyte epitope from tumor-associated antigen 90K. 2013 , 10, 275-82		11
140	Immune system targeting by biodegradable nanoparticles for cancer vaccines. 2013 , 168, 179-99		183
139	Human cancer regression antigens. 2013 , 25, 284-90		29
138	PMA withdrawal in PMA-treated monocytic THP-1 cells and subsequent retinoic acid stimulation, modulate induction of apoptosis and appearance of dendritic cells. 2013 , 46, 328-47		27
137	T cell-based gene therapy of cancer. 2013 , 161, 365-79		16
136	Biomarkers in Immunology. 2013 ,		
135	Adoptive cell therapies for glioblastoma. 2013 , 3, 275		38
134	T-Cell Receptor-Like Antibodies: Targeting the Intracellular Proteome Therapeutic Potential and Clinical Applications. 2013 , 2, 517-534		18
133	Identification of special AT-rich sequence binding protein 1 as a novel tumor antigen recognized by CD8+ T cells: implication for cancer immunotherapy. <i>PLoS ONE</i> , 2013 , 8, e56730	3-7	7
132	Clinical Significance of Immunohistochemical Expression of Cancer/Testis Tumor-associated Antigens (MAGE-A1, MAGE-A3/4, NY-ESO-1) in Patients with Non-small Cell Lung Cancer. 2014 , 100, 60-68		12
131	Manipulating Immune Regulatory Pathways to Enhance T Cell Stimulation. 2014 ,		3
130	Allogeneic tumor cell vaccines: the promise and limitations in clinical trials. 2014 , 10, 52-63		70
129	DNA vaccine for cancer immunotherapy. 2014 , 10, 3153-64		142
128	Peptide-based vaccines for cancer therapy. 2014 , 10, 3175-8		52

127	Implementing combinatorial immunotherapeutic regimens against cancer: The concept of immunological conditioning. <i>Onc Immunology</i> , 2014 , 3, e27588	7.2	12
126	Chemokine Gene-Modified Dendritic Cells for Cancer Therapy. 2014 , 301-314		
125	Frequent T cell responses against immunogenic targets in lung cancer patients for targeted immunotherapy. <i>Oncology Reports</i> , 2014 , 31, 384-90	3.5	15
124	Ephs and Ephrins in malignant gliomas. 2014 , 32, 190-201		17
123	Identification of erythropoietin receptor-derived peptides having the potential to induce cancer-reactive cytotoxic T lymphocytes from HLA-A24(+) patients with renal cell carcinoma. 2014 , 20, 59-65		7
122	Peptide vaccines for hematological malignancies: a missed promise?. 2014 , 99, 107-16		6
121	"In vitro" 3D models of tumor-immune system interaction. 2014 , 79-80, 145-54		63
120	Bioinformatics for cancer immunotherapy target discovery. <i>Cancer Immunology, Immunotherapy</i> , 2014 , 63, 1235-49	7.4	22
119	Immunoinformatics: a brief review. <i>Methods in Molecular Biology</i> , 2014 , 1184, 23-55	1.4	43
118	Functional TCR retrieval from single antigen-specific human T cells reveals multiple novel epitopes. <i>Cancer Immunology Research</i> , 2014 , 2, 1230-44	12.5	30
117	P53, hTERT, WT-1, and VEGFR2 are the most suitable targets for cancer vaccine therapy in HLA-A24 positive pancreatic adenocarcinoma. <i>Cancer Immunology, Immunotherapy</i> , 2014 , 63, 479-89	7.4	13
116	Krebs und das Immunsystem. 2014 , 29, 105-111		
115	Cancer-initiating cells from colorectal cancer patients escape from T cell-mediated immunosurveillance in vitro through membrane-bound IL-4. 2014 , 192, 523-32		80
114	Xenogeneic therapeutic cancer vaccines as breakers of immune tolerance for clinical application: to use or not to use?. 2014 , 32, 4015-24		21
113	CXorf61 is a target for T cell based immunotherapy of triple-negative breast cancer. <i>Oncotarget</i> , 2015 , 6, 25356-67	3.3	26
112	Targeting C-Type Lectin Receptors for Cancer Immunity. <i>Frontiers in Immunology</i> , 2015 , 6, 408	8.4	54
111	Peptide-Based Treatment: A Promising Cancer Therapy. <i>Journal of Immunology Research</i> , 2015 , 2015, 761820	4.5	79
110	Somatically mutated tumor antigens in the quest for a more efficacious patient-oriented immunotherapy of cancer. <i>Cancer Immunology, Immunotherapy</i> , 2015 , 64, 99-104	7.4	29

109	T Cell-Based Gene Therapy of Cancer. 2015 , 281-304		
108	The New Era of Cancer Immunotherapy: Manipulating T-Cell Activity to Overcome Malignancy. 2015 , 128, 1-68		34
107	Vaccination in Human Solid Tumors: Recent Progress in the Clinical Arena. 2015 , 41-46		
106	Receptor tyrosine kinase-like orphan receptor 1: a novel target for cancer immunotherapy. <i>Expert Opinion on Therapeutic Targets</i> , 2015 , 19, 941-55	6.4	26
105	Strategies for the identification of T cell-recognized tumor antigens in hematological malignancies for improved graft-versus-tumor responses after allogeneic blood and marrow transplantation. 2015 , 21, 1000-7		28
104	Nanoparticle-based immunotherapy for cancer. 2015 , 9, 16-30		322
103	Anticancer DNA vaccine based on human telomerase reverse transcriptase generates a strong and specific T cell immune response. <i>Onc Immunology</i> , 2016 , 5, e1083670	7.2	22
102	Solid-in-oil nanodispersions for transdermal drug delivery systems. 2016 , 11, 1375-1385		24
101	Adeno-associated virus (AAV) vectors in cancer gene therapy. 2016 , 240, 287-301		90
100	TANTIGEN: a comprehensive database of tumor T cell antigens. <i>Cancer Immunology, Immunotherapy</i> , 2017 , 66, 731-735	7.4	37
99	Receptor tyrosine kinase-like orphan receptor 1 (ROR-1): An emerging target for diagnosis and therapy of chronic lymphocytic leukemia. 2017 , 88, 814-822		18
98	The swinging pendulum of cancer immunotherapy personalization. 2017 , 14, 259-270		3
97	Human Tumor Antigens Yesterday, Today, and Tomorrow. <i>Cancer Immunology Research</i> , 2017 , 5, 347-354	12.5	55
96	Modern strategies and capabilities for activation of the immune response against tumor cells. <i>Tumor Biology</i> , 2017 , 39, 1010428317698380	2.9	3
95	A novel framework to improve MHC-I epitopes and break the tolerance to melanoma. <i>Onc Immunology</i> , 2017 , 6, e1319028	7.2	15
94	Research progress in advanced melanoma. <i>Cancer Letters</i> , 2017 , 397, 120-126	9.9	26
93	Immune targets and neoantigens for cancer immunotherapy and precision medicine. <i>Cell Research</i> , 2017 , 27, 11-37	24.7	139
92	Nanoparticulate Delivery of Cancer Cell Membrane Elicits Multiantigenic Antitumor Immunity. <i>Advanced Materials</i> , 2017 , 29, 1703969	24	260

91	Functional T cells targeting tumor-associated antigens are predictive for recurrence-free survival of patients with radically operated non-small cell lung cancer. <i>Onc Immunology</i> , 2017 , 6, e1360458	7.2	7
90	Iontophoresis and Electroporation. 2017 , 165-182		2
89	Neoantigens in immunotherapy and personalized vaccines: Implications for head and neck squamous cell carcinoma. <i>Oral Oncology</i> , 2017 , 71, 169-176	4.4	13
88	MAGE-A Antigens and Cancer Immunotherapy. <i>Frontiers in Medicine</i> , 2017 , 4, 18	4.9	39
87	A dual-function epidermal growth factor receptor pathway substrate 8 (Eps8)-derived peptide exhibits a potent cytotoxic T lymphocyte-activating effect and a specific inhibitory activity. <i>Cell Death and Disease</i> , 2018 , 9, 379	9.8	10
86	Mapping the tumour human leukocyte antigen (HLA) ligandome by mass spectrometry. <i>Immunology</i> , 2018 , 154, 331-345	7.8	57
85	Personalized neoantigen vaccines: A new approach to cancer immunotherapy. <i>Bioorganic and Medicinal Chemistry</i> , 2018 , 26, 2842-2849	3.4	59
84	Towards personalized, tumour-specific, therapeutic vaccines for cancer. <i>Nature Reviews Immunology</i> , 2018 , 18, 168-182	36.5	453
83	High adjuvant activity of layered double hydroxide nanoparticles and nanosheets in anti-tumour vaccine formulations. <i>Dalton Transactions</i> , 2018 , 47, 2956-2964	4.3	13
82	IgG response to MHC class I epitope peptides is a quantitative predictive biomarker in the early course of treatment of colorectal cancer using therapeutic peptides. <i>Oncology Reports</i> , 2018 , 39, 2385-2392	3.5	9
81	Nucleopore-Inspired Polymer Hydrogels for Selective Biomolecular Transport. <i>Biomacromolecules</i> , 2018 , 19, 3905-3916	6.9	18
80	Nature of tumour rejection antigens in ovarian cancer. <i>Immunology</i> , 2018 , 155, 202-210	7.8	8
79	Recent Advances in Targeting CD8 T-Cell Immunity for More Effective Cancer Immunotherapy. <i>Frontiers in Immunology</i> , 2018 , 9, 14	8.4	201
78	Current trends in Bioinformatics: An Insight. 2018 ,		
77	Immunotherapy in non-small-cell lung cancer: a bridge between research and clinical practice. <i>Future Oncology</i> , 2018 , 14, 41-60	3.6	7
76	Tools, Databases, and Applications of Immunoinformatics. 2018 , 159-174		
75	Role of tumor gene mutations in treatment response to immune checkpoint blockades. <i>Precision Clinical Medicine</i> , 2019 , 2, 100-109	6.7	5
74	Tumor-Specific Regulatory T Cells from the Bone Marrow Orchestrate Antitumor Immunity in Breast Cancer. <i>Cancer Immunology Research</i> , 2019 , 7, 1998-2012	12.5	8

73	Opportunities and Challenges for Antibodies against Intracellular Antigens. <i>Theranostics</i> , 2019 , 9, 7792-7806	18.06	8
72	TCR-like antibodies in cancer immunotherapy. <i>Journal of Hematology and Oncology</i> , 2019 , 12, 99	22.4	17
71	Proteomic characterization of outer membrane vesicles from gut mucosa-derived fusobacterium nucleatum. <i>Journal of Proteomics</i> , 2019 , 195, 125-137	3.9	21
70	T-cell receptor mimic (TCRm) antibody therapeutics against intracellular proteins. <i>Antibody Therapeutics</i> , 2019 , 2, 22-32	5.8	6
69	Expressions of HLA Class II Genes in Cutaneous Melanoma Were Associated with Clinical Outcome: Bioinformatics Approaches and Systematic Analysis of Public Microarray and RNA-Seq Datasets. <i>Diagnostics</i> , 2019 , 9,	3.8	5
68	Induction of tumor-specific CTL responses using the C-terminal fragment of Viral protein R as cell penetrating peptide. <i>Scientific Reports</i> , 2019 , 9, 3937	4.9	9
67	Therapeutic approaches for targeting receptor tyrosine kinase like orphan receptor-1 in cancer cells. <i>Expert Opinion on Therapeutic Targets</i> , 2019 , 23, 447-456	6.4	5
66	Targeting cancers through TCR-peptide/MHC interactions. <i>Journal of Hematology and Oncology</i> , 2019 , 12, 139	22.4	33
65	Tumor Antigens. 2019 , 61-74		2
64	Cancer Neoantigens. <i>Annual Review of Immunology</i> , 2019 , 37, 173-200	34.7	219
63	Protein-based nanoparticles in cancer vaccine development. <i>Nanomedicine: Nanotechnology, Biology, and Medicine</i> , 2019 , 15, 164-174	6	69
62	Irradiated lactic acid-stimulated tumour cells promote the antitumour immunity as a therapeutic vaccine. <i>Cancer Letters</i> , 2020 , 469, 367-379	9.9	3
61	Efficient induction of cytotoxic T lymphocytes in hepatocellular carcinoma using the HLA-A2-restricted survivin peptide in vitro. <i>Experimental Cell Research</i> , 2020 , 386, 111741	4.2	2
60	Single-Domain Antibody-Based TCR-Like CAR-T: A Potential Cancer Therapy. <i>Journal of Immunology Research</i> , 2020 , 2020, 2454907	4.5	1
59	Emerging roles of the MAGE protein family in stress response pathways. <i>Journal of Biological Chemistry</i> , 2020 , 295, 16121-16155	5.4	12
58	Oncolytic Measles Virus Encoding Interleukin-12 Mediated Antitumor Activity and Immunologic Control of Colon Cancer and. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2021 , 36, 774-782	3.9	4
57	T-cell receptor affinity in the age of cancer immunotherapy. <i>Molecular Carcinogenesis</i> , 2020 , 59, 862-870	5	7
56	Tumor antigens heterogeneity and immune response-targeting neoantigens in breast cancer. <i>Seminars in Cancer Biology</i> , 2021 , 72, 65-75	12.7	14

55	Effects and mechanisms of Eps8 on the biological behaviour of malignant tumours (Review). <i>Oncology Reports</i> , 2021 , 45, 824-834	3.5	1
54	Genetic Bias, Diversity Indices, Physiochemical Properties and CDR3 Motifs Divide Auto-Reactive from Allo-Reactive T-Cell Repertoires. <i>International Journal of Molecular Sciences</i> , 2021 , 22,	6.3	2
53	Phase I/II trial of a long peptide vaccine (LPV7) plus toll-like receptor (TLR) agonists with or without incomplete Freund® adjuvant (IFA) for resected high-risk melanoma. 2021 , 9,		4
52	Integrating Cancer Vaccines in the Standard-of-Care of Ovarian Cancer: Translating Preclinical Models to Human. <i>Cancers</i> , 2021 , 13,	6.6	1
51	Personalized cancer immunotherapy. 2022 , 399-426		
50	Molecular chaperones and cancer immunotherapy. <i>Handbook of Experimental Pharmacology</i> , 2006 , 305-292		19
49	Predictive Models in Tumor Immunology. 2008 , 1-22		2
48	Preparation of polypeptides comprising multiple TAA peptides. <i>Methods in Molecular Biology</i> , 2014 , 1139, 357-66	1.4	2
47	Pulsing dendritic cells with whole tumor cell lysates. <i>Methods in Molecular Biology</i> , 2014 , 1139, 27-31	1.4	13
46	Resistance of Cancer Stem Cells to Cell-Mediated Immune Responses. <i>Resistance To Targeted Anti-cancer Therapeutics</i> , 2015 , 3-29	0.3	2
45	Therapeutic vaccination for the treatment of malignant melanoma. <i>Recent Results in Cancer Research</i> , 2007 , 176, 219-27	1.5	8
44	Encyclopedia of Immunotoxicology. 2014 , 1-7		1
43	Dendritic cell-tumor cell fusion vaccines. <i>Advances in Experimental Medicine and Biology</i> , 2011 , 713, 177-866	3.6	4
42	Vaccines for Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2006 , 1, 93-104	8.9	19
41	Relating TCR-peptide-MHC affinity to immunogenicity for the design of tumor vaccines. <i>Journal of Clinical Investigation</i> , 2006 , 116, 2543-51	15.9	85
40	Rapid T cell-based identification of human tumor tissue antigens by automated two-dimensional protein fractionation. <i>Journal of Clinical Investigation</i> , 2010 , 120, 2230-42	15.9	17
39	Antigen-specific Tregs control T cell responses against a limited repertoire of tumor antigens in patients with colorectal carcinoma. <i>Journal of Clinical Investigation</i> , 2009 , 119, 3311-21	15.9	155
38	Coupling of Peptides to the Surface of Liposomes Application to Liposome-Based Synthetic Vaccines. 2006 , 111-130		2

37	Evolutionary history of the cancer immunity antigen MAGE gene family. <i>PLoS ONE</i> , 2011 , 6, e20365	3.7	29
36	Progress in the treatment of advanced prostate cancer. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2014 , 117-31	7.1	29
35	The anti-apoptotic members of the Bcl-2 family are attractive tumor-associated antigens. <i>Oncotarget</i> , 2010 , 1, 239-245	3.3	35
34	Parity improves anti-tumor immunity in breast cancer patients. <i>Oncotarget</i> , 2017 , 8, 104981-104991	3.3	3
33	Protein Misfolding Diseases and Therapeutic Approaches. <i>Current Protein and Peptide Science</i> , 2019 , 20, 1226-1245	2.8	10
32	Cytomegalovirus and tumors: two players for one goal-immune escape. <i>The Open Virology Journal</i> , 2011 , 5, 60-9	1.9	15
31	Immunotherapeutic strategies: the melanoma example. <i>Immunotherapy</i> , 2009 , 1, 679-90	3.8	9
30	Cross-immunizing potential of tumor MAGE-A epitopes recognized by HLA-A*02:01-restricted cytotoxic T lymphocytes. <i>BMB Reports</i> , 2012 , 45, 408-13	5.5	2
29	Peptide Vaccines for Cancer Treatment. 2006 , 499-505		
28	Immunology of Cancer. 2008 , 1947-1963		
27	Respiratory Homeostasis and Exploitation of the Immune System for Lung Cancer Vaccines. <i>Oncology & Hematology Review</i> , 2009 , 58, 40-48	0.1	
26	Immunit�et nouvelles voies th�rapeutiques dans le m�lanome. <i>Bulletin De L'Academie Nationale De Medecine</i> , 2010 , 194, 1373-1381	0.1	
25	Dendritic Cell-Based Cancer Vaccines: Practical Considerations. 2011 , 107-126		
24	Computational Models as Novel Tools for Cancer Vaccines. <i>SIMAI Springer Series</i> , 2012 , 227-248		
23	Basic Principles of Immunology in Urology. 2012 , 495-529.e5		
22	Melanoma vaccines in development. 2012 , 104-119		
21	In Silico Investigation of Cancer Using Publicly Available Data. 2014 , 327-351		
20	Ex vivo loading of autologous dendritic cells with tumor antigens. <i>Methods in Molecular Biology</i> , 2014 , 1139, 41-4	1.4	2

19	Immunopathology of Head and Neck Tumors and Immunotherapy of Squamous Cell Carcinoma. 2015 , 299-311		
18	Aliphatic Polyesters: Particulate Vaccine Delivery. 147-185		
17	Chapter 9: Update on Nanoparticle-Mediated Immune Mechanisms for Dendritic Cell-Based Targeted Immunity and Cancer. 2017 , 235-264		
16	Focus on TILs: Prognostic significance of tumor infiltrating lymphocytes in human glioma. <i>Cancer Immunity</i> , 2007 , 7, 12		94
15	The anti-apoptotic members of the Bcl-2 family are attractive tumor-associated antigens. <i>Oncotarget</i> , 2010 , 1, 239-45	3.3	20
14	Nanovesicle-mediated targeted delivery of immune checkpoint blockades to potentiate therapeutic efficacy and prevent side effects.. <i>Advanced Materials</i> , 2021 , e2106516	24	4
13	Tumor antigens for preventative cancer vaccines. 2022 , 51-74		
12	Cancer vaccines as promising immuno-therapeutics: platforms and current progress.. <i>Journal of Hematology and Oncology</i> , 2022 , 15, 28	22.4	16
11	In vitro and in vivo evaluation of DC-targeting PLGA nanoparticles encapsulating heparanase CD4 and CD8 T-cell epitopes for cancer immunotherapy.. <i>Cancer Immunology, Immunotherapy</i> , 2022 ,	7.4	0
10	Peptide vaccine-treated, long-term surviving cancer patients harbor self-renewing tumor-specific CD8+ T cells. <i>Nature Communications</i> , 2022 , 13,	17.4	0
9	Single-cell RNA-seq-based proteogenomics identifies glioblastoma-specific transposable elements encoding HLA-I-presented peptides. <i>Cell Reports</i> , 2022 , 39, 110916	10.6	1
8	Evaluation of chimeric antigen receptor of humanized rabbit-derived T cell receptor-like antibody. <i>Cancer Science</i> ,	6.9	
7	Role of Immune Cells and Receptors in Cancer Treatment: An Immunotherapeutic Approach. 2022 , 10, 1493		0
6	Nanobody-based CAR T cells targeting intracellular tumor antigens. 2022 , 156, 113919		0
5	Mutant and non-mutant neoantigen-based cancer vaccines: recent advances and future promises. 746-762		0
4	Supramolecular assembly of a trivalent peptide hydrogel vaccine for cancer immunotherapy. 2023 ,		0
3	Tyrosinase-Related Protein2 Peptide with Replacement of N-Terminus Residue by Cysteine Binds to H-2Kb and Induces Antigen-Specific Cytotoxic T Lymphocytes after Conjugation with CpG-DNA.		0
2	mRNA-Based Therapeutics in Cancer Treatment. 2023 , 15, 622		0

- 1 Determining role of thymus in immune pathogenesis of autoimmune, oncological and infectious diseases. **2023**, 25, 39-58

o